Hope Therapeutics to Deploy Emobot AI Platform, Expecting to Double Patient Success Rates
Hope Therapeutics partners with Emobot Health to deploy its AI-powered “Depression Thermometer” across its interventional psychiatry clinic network, leveraging facial expression, voice tone and actigraphy analysis. Clinical validation showed r=0.89 concordance with MADRS and the integration aims to double patient success rates via real-time relapse detection.
1. Partnership Details
Hope Therapeutics subsidiary NRx deploys Emobot’s AI-powered “Depression Thermometer” across its interventional psychiatry clinics, integrating facial expression, voice tone and actigraphy analysis into patient monitoring via a passive smartphone app.
2. Clinical Validation
A pooled analysis of three prospective studies (EMC1, EMC2-FR, EMC2-BD) demonstrated strong concordance with MADRS (r=0.89) and PHQ-9 (r=0.83), validating the platform as an objective, real-time biomarker for depressive symptom severity.
3. Impact on Patient Outcomes
The integration is expected to double patient success rates by enabling immediate “recapture” interventions—such as maintenance ketamine or TMS sessions—when early relapse signals are detected between clinic visits.
4. Roll-Out and Patient App Features
Initial roll-out in Hope’s Florida clinics includes automatic in-app alerts and appointment scheduling for flagged relapse risks, with plans to expand nationwide by end of 2026 to cover a broader patient base.